Saturday, 31 October 2026European Markets

AUTOSTORE HOLDINGS Stock Bearish Momentum With A 9% Drop So Far On Friday

Loading stream...

(VIANEWS) - Shares of AUTOSTORE HOLDINGS (Oslo Børs Benchmark Index_GI: AUTO.OL) slid 9.12% to kr22.72 at 14:23 EST on Friday, following the last session's upward trend. Oslo Børs Benchmark Index_GI is jumping 0.17% to kr1,215.27, after two successive sessions in a row of gains. This seems, up until now, a somewhat bullish trend trading session today.

About AUTOSTORE HOLDINGS

AutoStore Holdings Ltd., a robotic and software technology company, provides warehouse automation solutions in Norway, rest of Nordics, Germany, rest of Europe, the United States, Asia, and internationally. It offers grids, bins, robots, workstations, controllers, and spare parts. The company also provides warehouse management software. It serves retail, grocery, third party logistic, industrial, and healthcare industries. The company was formerly known as AutoStore NewCo Ltd. and changed its name to AutoStore Holdings Ltd. in October 2021. AutoStore Holdings Ltd. was founded in 1996 and is headquartered in Nedre Vats, Norway.

Earnings Per Share

As for profitability, AUTOSTORE HOLDINGS has a trailing twelve months EPS of kr0.23.

PE Ratio

AUTOSTORE HOLDINGS has a trailing twelve months price to earnings ratio of 98.78. Meaning, the purchaser of the share is investing kr98.78 for every norwegian krone of annual earnings.

More news about AUTOSTORE HOLDINGS (AUTO.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com